416 related articles for article (PubMed ID: 29241892)
1. Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.
Dilokthornsakul P; Patidar M; Campbell JD
Value Health; 2017 Dec; 20(10):1329-1335. PubMed ID: 29241892
[TBL] [Abstract][Full Text] [Related]
2. Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation.
Dilokthornsakul P; Hansen RN; Campbell JD
Eur Respir J; 2016 Jun; 47(6):1697-705. PubMed ID: 27126691
[TBL] [Abstract][Full Text] [Related]
3. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Wainwright CE; Elborn JS; Ramsey BW; Marigowda G; Huang X; Cipolli M; Colombo C; Davies JC; De Boeck K; Flume PA; Konstan MW; McColley SA; McCoy K; McKone EF; Munck A; Ratjen F; Rowe SM; Waltz D; Boyle MP; ;
N Engl J Med; 2015 Jul; 373(3):220-31. PubMed ID: 25981758
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
[TBL] [Abstract][Full Text] [Related]
5. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
Boyle MP; Bell SC; Konstan MW; McColley SA; Rowe SM; Rietschel E; Huang X; Waltz D; Patel NR; Rodman D;
Lancet Respir Med; 2014 Jul; 2(7):527-38. PubMed ID: 24973281
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States.
Sharma D; Xing S; Hung YT; Caskey RN; Dowell ML; Touchette DR
Orphanet J Rare Dis; 2018 Sep; 13(1):172. PubMed ID: 30268148
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
8. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
[TBL] [Abstract][Full Text] [Related]
9. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS
Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
Vadagam P; Kamal KM; Covvey JR; Giannetti V; Mukherjee K
J Manag Care Spec Pharm; 2018 Oct; 24(10):987-997. PubMed ID: 30247102
[TBL] [Abstract][Full Text] [Related]
11. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
12. Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease.
Hubert D; Chiron R; Camara B; Grenet D; Prévotat A; Bassinet L; Dominique S; Rault G; Macey J; Honoré I; Kanaan R; Leroy S; Desmazes Dufeu N; Burgel PR
J Cyst Fibros; 2017 May; 16(3):388-391. PubMed ID: 28325531
[TBL] [Abstract][Full Text] [Related]
13. Effects of Lumacaftor/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis.
Savi D; Schiavetto S; Simmonds NJ; Righelli D; Palange P
J Cyst Fibros; 2019 May; 18(3):420-424. PubMed ID: 30879989
[TBL] [Abstract][Full Text] [Related]
14. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results.
Murer C; Huber LC; Kurowski T; Hirt A; Robinson CA; Bürgi U; Benden C
Swiss Med Wkly; 2018; 148():w14593. PubMed ID: 29451946
[TBL] [Abstract][Full Text] [Related]
15. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.
Rubin JL; O'Callaghan L; Pelligra C; Konstan MW; Ward A; Ishak JK; Chandler C; Liou TG
Ther Adv Respir Dis; 2019; 13():1753466618820186. PubMed ID: 30803355
[TBL] [Abstract][Full Text] [Related]
16. Effects of Lumacaftor-Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging, and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Boutin S; Wielpütz MO; Joachim C; Frey DL; Wege S; Sommerburg O; Kauczor HU; Stahl M; Dalpke AH; Mall MA
Ann Am Thorac Soc; 2021 Jun; 18(6):971-980. PubMed ID: 33600745
[No Abstract] [Full Text] [Related]
17. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
[No Abstract] [Full Text] [Related]
18. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
[TBL] [Abstract][Full Text] [Related]
19. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Rehman A; Baloch NU; Janahi IA
N Engl J Med; 2015 Oct; 373(18):1783. PubMed ID: 26510035
[No Abstract] [Full Text] [Related]
20. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
Talamo Guevara M; McColley SA
Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
